The collection of ctDNA typically involves a simple blood draw, often referred to as a "liquid biopsy." The blood sample is then processed to extract cfDNA, which includes ctDNA. Advanced molecular techniques such as next-generation sequencing (NGS) and digital PCR (dPCR) are used to analyze these DNA fragments. These techniques enable high sensitivity and specificity in detecting tumor-specific genetic alterations.
